1. Home
  2. CLRB vs HSPO Comparison

CLRB vs HSPO Comparison

Compare CLRB & HSPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLRB
  • HSPO
  • Stock Information
  • Founded
  • CLRB 2002
  • HSPO 2014
  • Country
  • CLRB United States
  • HSPO United States
  • Employees
  • CLRB N/A
  • HSPO N/A
  • Industry
  • CLRB Biotechnology: Pharmaceutical Preparations
  • HSPO Blank Checks
  • Sector
  • CLRB Health Care
  • HSPO Finance
  • Exchange
  • CLRB Nasdaq
  • HSPO Nasdaq
  • Market Cap
  • CLRB 76.0M
  • HSPO 87.7M
  • IPO Year
  • CLRB N/A
  • HSPO 2022
  • Fundamental
  • Price
  • CLRB $2.06
  • HSPO $11.20
  • Analyst Decision
  • CLRB Strong Buy
  • HSPO
  • Analyst Count
  • CLRB 2
  • HSPO 0
  • Target Price
  • CLRB $21.00
  • HSPO N/A
  • AVG Volume (30 Days)
  • CLRB 213.0K
  • HSPO 23.1K
  • Earning Date
  • CLRB 10-31-2024
  • HSPO 01-01-0001
  • Dividend Yield
  • CLRB N/A
  • HSPO N/A
  • EPS Growth
  • CLRB N/A
  • HSPO N/A
  • EPS
  • CLRB N/A
  • HSPO 0.33
  • Revenue
  • CLRB N/A
  • HSPO N/A
  • Revenue This Year
  • CLRB N/A
  • HSPO N/A
  • Revenue Next Year
  • CLRB N/A
  • HSPO N/A
  • P/E Ratio
  • CLRB N/A
  • HSPO $34.11
  • Revenue Growth
  • CLRB N/A
  • HSPO N/A
  • 52 Week Low
  • CLRB $1.82
  • HSPO $10.57
  • 52 Week High
  • CLRB $4.45
  • HSPO $11.25
  • Technical
  • Relative Strength Index (RSI)
  • CLRB 47.07
  • HSPO 49.69
  • Support Level
  • CLRB $2.09
  • HSPO $11.17
  • Resistance Level
  • CLRB $2.10
  • HSPO $11.25
  • Average True Range (ATR)
  • CLRB 0.10
  • HSPO 0.00
  • MACD
  • CLRB -0.00
  • HSPO -0.00
  • Stochastic Oscillator
  • CLRB 17.39
  • HSPO 0.00

About CLRB Cellectar Biosciences Inc.

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

Share on Social Networks: